ticlopidine and Diabetes Mellitus studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.

Research Excerpts

Excerpt	Relevance	Reference
" Ticagrelor demonstrated a more rapid onset and greater magnitude of platelet inhibition than clopidogrel in Hispanic patients with stable coronary artery disease (CAD)."	9.20	Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus. ( Angiolillo, DJ; Caplan, R; Carlson, G; Clavijo, LC; Maya, J; Price, MJ; Teng, R, 2015)
"Diabetes mellitus (DM) is associated with impaired platelet response to clopidogrel."	9.19	Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status. ( Abbate, R; Angiolillo, DJ; Bellandi, F; Giusti, B; Leoncini, M; Maioli, M; Marcucci, R; Toso, A, 2014)
"Diabetes mellitus (DM) is the most important predictor of chronic kidney disease (CKD), and pharmacodynamic (PD) studies have shown that DM patients with impaired renal function are characterized by reduced clopidogrel response."	9.17	Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Kodali, MK; Patel, R; Rollini, F; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2013)
"We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)."	9.13	Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008)
"Clinical and genetic factors had a differential effect on a P2Y12 inhibitor reactivity with clopidogrel and prasugrel in patients with coronary artery disease."	8.12	Differential Impact of Clinical and Genetic Factors on High Platelet Reactivity in Patients with Coronary Artery Disease Treated with Clopidogrel and Prasugrel. ( Ariyoshi, N; Kitahara, H; Kobayashi, Y; Nishi, T; Ohno, Y; Saito, Y; Wakabayashi, S, 2022)
"Diabetes mellitus (DM) is associated with enhanced platelet reactivity and impaired response to oral antiplatelet therapy, including clopidogrel."	7.85	Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. ( Angiolillo, DJ; Carlson, GF; Dangas, G; Franchi, F; Khan, ND; Mehran, R; Raveendran, G; Rollini, F; Sweeny, JM; Teng, R; Waksman, R; Zhao, Y, 2017)
" Diabetes mellitus and current smoker status were independent factors related to reactivity to clopidogrel."	7.83	Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures. ( Hironaka, Y; Kichikawa, K; Motoyama, Y; Nakagawa, I; Nakase, H; Park, HS; Takayama, K; Wada, T; Yokoyama, S, 2016)
"The aim of this analysis was to determine the effect of prolonging clopidogrel therapy >12 months versus ≤12 months after PCI on very late outcomes in patients with diabetes mellitus (DM)."	7.81	Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting. ( Agrawal, K; Cho, K; Dufour, AB; Faxon, DP; Gagnon, DR; Gaziano, JM; Kinlay, S; Ly, S; Prince, L; Smoot, KJ; Sokolovskaya, G; Temiyasathit, S; Thukkani, AK, 2015)
"To estimate the clinical effectiveness associated with clopidogrel treatment after myocardial infarction (MI) in patients with diabetes."	7.78	Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes. ( Andersson, C; Gislason, GH; Køber, L; Lyngbæk, S; Nguyen, CD; Nielsen, M; Torp-Pedersen, C, 2012)
" However, the effects of EV-077 on pharmacodynamic (PD) profiles in patients with DM and coronary artery disease (CAD) while on antiplatelet therapy is poorly explored and represented the aim of this in vitro pilot investigation."	6.79	Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. ( Angiolillo, DJ; Bender, N; Darlington, A; Desai, B; Franchi, F; Muñiz-Lozano, A; Patel, R; Rollini, F; Sakariassen, KS; Tello-Montoliu, A; Wilson, RE, 2014)
"Cilostazol is a platelet inhibitor which when added to aspirin and clopidogrel has shown to reduce the risk of recurrent ischaemic events without an increase in bleeding."	6.76	Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. ( Angiolillo, DJ; Bass, TA; Box, LC; Capodanno, D; Capranzano, P; Charlton, RK; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Guzman, LA; Sumner, S; Ueno, M; Zenni, M, 2011)
"Diabetes mellitus is an independent predictor of adverse clinical events after drug-eluting stent implantation."	5.39	Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. ( Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G, 2013)
"The use of a high loading dose of clopidogrel (600 mg) in patients undergoing elective PCI can overcome the significant increase in post-PCI platelet aggregation and rate of acute cardiac events induced by diabetes mellitus as co-morbidity in those patients."	5.22	The impact of a 600-mg loading dose of clopidogrel in diabetic and non-diabetic patients undergoing elective PCI. ( Abd Elghany, M; Farid, SF; Mohareb, MW; Sabry, NA, 2016)
" Ticagrelor demonstrated a more rapid onset and greater magnitude of platelet inhibition than clopidogrel in Hispanic patients with stable coronary artery disease (CAD)."	5.20	Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus. ( Angiolillo, DJ; Caplan, R; Carlson, G; Clavijo, LC; Maya, J; Price, MJ; Teng, R, 2015)
"Diabetes mellitus (DM) is associated with impaired platelet response to clopidogrel."	5.19	Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status. ( Abbate, R; Angiolillo, DJ; Bellandi, F; Giusti, B; Leoncini, M; Maioli, M; Marcucci, R; Toso, A, 2014)
"Diabetes mellitus (DM) is the most important predictor of chronic kidney disease (CKD), and pharmacodynamic (PD) studies have shown that DM patients with impaired renal function are characterized by reduced clopidogrel response."	5.17	Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Kodali, MK; Patel, R; Rollini, F; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2013)
"We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)."	5.13	Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008)
"Clinical and genetic factors had a differential effect on a P2Y12 inhibitor reactivity with clopidogrel and prasugrel in patients with coronary artery disease."	4.12	Differential Impact of Clinical and Genetic Factors on High Platelet Reactivity in Patients with Coronary Artery Disease Treated with Clopidogrel and Prasugrel. ( Ariyoshi, N; Kitahara, H; Kobayashi, Y; Nishi, T; Ohno, Y; Saito, Y; Wakabayashi, S, 2022)
"Diabetes mellitus (DM) is associated with enhanced platelet reactivity and impaired response to oral antiplatelet therapy, including clopidogrel."	3.85	Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. ( Angiolillo, DJ; Carlson, GF; Dangas, G; Franchi, F; Khan, ND; Mehran, R; Raveendran, G; Rollini, F; Sweeny, JM; Teng, R; Waksman, R; Zhao, Y, 2017)
" Patients with known diabetes mellitus received clopidogrel in 51% of the cases, whereas most patients with hyperglycemia (72%) received a new P2Y12 inhibitor: according to clinical presentation in case STEMI prasugrel/ticagrelor were more prescribed than clopidogrel (70 vs."	3.85	Management of diabetic patients hospitalized for acute coronary syndromes: a prospective multicenter registry. ( Bognetti, P; Cardile, A; De Servi, S; Demarchi, A; Ferlini, M; Frattini, S; Grieco, N; Ielasi, A; Lettieri, C; Mafrici, A; Musumeci, G; Rossini, R; Russo, A; Sponzilli, C; Vecchiato, C; Visconti, LO, 2017)
"To describe contemporary trends of P2Y12 inhibitor use in patients with acute coronary syndrome (ACS) and comorbid diabetes mellitus (DM) and/or chronic kidney disease (CKD) who have a higher risk of recurring ACS and may benefit from treatment with higher efficacy third-generation agents (prasugrel and ticagrelor)."	3.85	Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease. ( Desai, RJ; Gagne, JJ; Mogun, H; Spoendlin, J, 2017)
" The aim of the study was to verify whether clopidogrel response measured by Multiplate analyzer (ADPtest) in diabetic ACS patients treated with PCI predicts the risk of stent thrombosis or cardiovascular mortality and bleeding."	3.83	Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome. ( Bekta, P; Chmielak, Z; Debski, A; Jamiolkowski, J; Klopotowski, M; Kukula, K; Kunicki, PK; Polanska-Skrzypczyk, M; Witkowski, A, 2016)
" Diabetes mellitus and current smoker status were independent factors related to reactivity to clopidogrel."	3.83	Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures. ( Hironaka, Y; Kichikawa, K; Motoyama, Y; Nakagawa, I; Nakase, H; Park, HS; Takayama, K; Wada, T; Yokoyama, S, 2016)
" In patients treated with ASA (100-160 mg) and clopidogrel (75 mg daily) or ticagrelor (90 mg twice a day) platelet reactivity and the reticulated platelets fraction (immature platelets fraction, IPF) were assessed at 30-90 days post-discharge for an acute coronary syndrome or elective PCI."	3.83	Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy. ( Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M, 2016)
"Dual-antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB)."	3.83	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. ( Ariti, C; Baber, U; Chieffo, A; Cohen, DJ; Colombo, A; Dangas, G; Gibson, CM; Giustino, G; Henry, TD; Kini, AS; Kirtane, AJ; Krucoff, MW; Litherland, C; Mehran, R; Moliterno, DJ; Pocock, S; Sartori, S; Steg, PG; Stone, GW; Weisz, G; Witzenbichler, B, 2016)
" No data exist about the impact of HRPR after 600 mg clopidogrel loading on long-term clinical outcome in patients with diabetes mellitus and treated with percutaneous coronary angioplasty (PCI) for chronic total occlusion (CTO)."	3.81	Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus. ( Abbate, R; Antoniucci, D; Cantini, G; Carrabba, N; Cerisano, G; Comito, V; Gensini, GF; Gori, AM; Marcucci, R; Marrani, M; Migliorini, A; Parodi, G; Valenti, R; Vergara, R, 2015)
"The aim of this analysis was to determine the effect of prolonging clopidogrel therapy >12 months versus ≤12 months after PCI on very late outcomes in patients with diabetes mellitus (DM)."	3.81	Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting. ( Agrawal, K; Cho, K; Dufour, AB; Faxon, DP; Gagnon, DR; Gaziano, JM; Kinlay, S; Ly, S; Prince, L; Smoot, KJ; Sokolovskaya, G; Temiyasathit, S; Thukkani, AK, 2015)
"Diabetes mellitus (DM) is associated with increased platelet activation and reduced platelet inhibition by clopidogrel."	3.79	Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin. ( Desta, Z; Flockhart, DA; Jin, Y; Kovacs, R; Kreutz, RP; Kreutz, Y; Miao, J; Nystrom, P, 2013)
"To estimate the clinical effectiveness associated with clopidogrel treatment after myocardial infarction (MI) in patients with diabetes."	3.78	Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes. ( Andersson, C; Gislason, GH; Køber, L; Lyngbæk, S; Nguyen, CD; Nielsen, M; Torp-Pedersen, C, 2012)
"We sought to assess the impact of renal function on platelet reactivity in patients with diabetes mellitus (DM) and coronary artery disease on aspirin and clopidogrel therapy."	3.76	Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. ( Alfonso, F; Angiolillo, DJ; Bass, TA; Bernardo, E; Capodanno, D; Fernandez-Ortiz, A; Ferreiro, JL; Jimenez-Quevedo, P; Macaya, C; Sabaté, M; Ueno, M; Vivas, D, 2010)
"(1) Aspirin reduces the risk of myocardial infarction in men over 40 with no history of cardiovascular disease, and in hypertensive patients of both sexes over that age."	3.70	Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention. ( , 2000)
"Elderly men are more likely than elderly women to receive aspirin and ticlopidine and equally like to receive warfarin after a stroke."	3.70	Sex differences and similarities in the management and outcome of stroke patients. ( Austin, PC; Holroyd-Leduc, JM; Kapral, MK; Tu, JV, 2000)
" However, the effects of EV-077 on pharmacodynamic (PD) profiles in patients with DM and coronary artery disease (CAD) while on antiplatelet therapy is poorly explored and represented the aim of this in vitro pilot investigation."	2.79	Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. ( Angiolillo, DJ; Bender, N; Darlington, A; Desai, B; Franchi, F; Muñiz-Lozano, A; Patel, R; Rollini, F; Sakariassen, KS; Tello-Montoliu, A; Wilson, RE, 2014)
"Cilostazol is a platelet inhibitor which when added to aspirin and clopidogrel has shown to reduce the risk of recurrent ischaemic events without an increase in bleeding."	2.76	Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. ( Angiolillo, DJ; Bass, TA; Box, LC; Capodanno, D; Capranzano, P; Charlton, RK; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Guzman, LA; Sumner, S; Ueno, M; Zenni, M, 2011)
"Hypertension was seen in 55% of all occlusions, hyperlipaemia in 33%, and diabetes in 29%."	2.65	The influence of ticlopidine on the natural course of retinal vein occlusion. ( Baarsma, GS; Henkes, HE; Houtsmuller, AJ; Klompe, M; Tijssen, J; Vermeulen, JA; Zahn, KJ, 1984)
"Diabetes mellitus is commonly associated with both microvascular and macrovascular complications (coronary artery disease, cerebrovascular events, severe peripheral vascular disease, nephropathy and retinopathy)."	2.45	Diabetes, vascular complications and antiplatelet therapy: open problems. ( Cerbone, AM; Coppola, A; Di Minno, G; Macarone-Palmieri, N; Rivellese, AA; Saldalamacchia, G, 2009)
"High interindividual variability in clinical outcomes following clopidogrel's standard dosing regimen continues to be a challenge even two decades after its approval."	1.46	Identifying clinically relevant sources of variability: The clopidogrel challenge. ( Horenstein, RB; Jiang, XL; Lesko, LJ; Lewis, JP; Peletier, LA; Samant, S; Schmidt, S; Shuldiner, AR, 2017)
"Diabetes mellitus is an independent predictor of adverse clinical events after drug-eluting stent implantation."	1.39	Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. ( Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G, 2013)
"Medical records of 659 patients treated for myocardial infarction at the 1st Department of Internal Medicine-Cardiology of Borsod-Abaúj-Zemplén County Hospital and University Hospital were analyzed."	1.39	Pharmaceutical care for patients with acute myocardial infarction in Hungary. ( Argay, M; Dormaeva, I; Hankó, B; Koós, I; Meskó, A; Takács, I; Zelkó, R, 2013)
" The incidence of major adverse cardiac events was collected at 4 years."	1.36	Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. ( Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C, 2010)
" We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and angiographic stent thrombosis during 2-year follow-up."	1.34	Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. ( Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E, 2007)

Research

Studies (105)

Authors

Clinical Trials (18)

Trial Overview

Trial Outcomes

Inhibition of the P2Y12 Receptor at 2 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by P2Y12 Reaction Units (PRU) From VerifyNow™

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (1.90)	18.7374
1990's	2 (1.90)	18.2507
2000's	30 (28.57)	29.6817
2010's	66 (62.86)	24.3611
2020's	5 (4.76)	2.80

Authors	Studies
Altınay, L	1
Çetin, E	1
Piccin Padilla, M	1
Macedo, LSDN	1
França, ACW	1
Meirelles, I	1
Magliano, CADS	1
Santos, MDS	1
Cha, JJ	1
Cho, JY	1
Lim, S	1
Kim, JH	2
Joo, HJ	1
Park, JH	2
Hong, SJ	1
Lim, DS	1
Kook, H	1
Lee, SH	1
Ko, YG	1
Min, PK	1
Lee, JH	2
Yoon, CH	2
Chae, IH	2
Lee, SW	2
Lee, SR	1
Choi, SH	2
Koh, YS	1
Yu, CW	1
Capranzano, P	3
Angiolillo, DJ	13
Verdoia, M	2
Pergolini, P	2
Nardin, M	2
Rolla, R	2
Negro, F	1
Gioscia, R	1
Fierro, N	1
Saghir Afifeh, AM	1
Viglione, F	1
Suryapranata, H	2
De Luca, G	2
Saito, Y	1
Nishi, T	1
Wakabayashi, S	1
Ohno, Y	1
Kitahara, H	1
Ariyoshi, N	1
Kobayashi, Y	1
Sweeny, JM	1
Franchi, F	2
Rollini, F	3
Waksman, R	1
Raveendran, G	1
Dangas, G	2
Khan, ND	1
Carlson, GF	1
Zhao, Y	1
Teng, R	2
Mehran, R	5
Dalby, AJ	1
Gottlieb, S	1
Cyr, DD	1
Magnus Ohman, E	1
McGuire, DK	1
Ruzyllo, W	1
Bhatt, DL	5
Wiviott, SD	1
Winters, KJ	1
Fox, KAA	1
Armstrong, PW	1
White, HD	1
Prabhakaran, D	1
Roe, MT	1
Ferlini, M	1
Musumeci, G	1
Demarchi, A	1
Grieco, N	1
Mafrici, A	1
De Servi, S	3
Rossini, R	1
Sponzilli, C	1
Bognetti, P	1
Cardile, A	1
Frattini, S	1
Ielasi, A	1
Russo, A	1
Vecchiato, C	1
Lettieri, C	1
Visconti, LO	1
Erathi, HV	1
Durgaprasad, R	1
Velam, V	1
Pvgk, S	1
Rodda, M	1
C, K	1
Kanavath, SN	1
Desai, RJ	1
Spoendlin, J	1
Mogun, H	1
Gagne, JJ	1
Hamilos, M	1
Petousis, S	1
Xanthopoulou, I	1
Goudevenos, J	1
Kanakakis, J	1
Sitafidis, G	1
Vavouranakis, M	1
Skalidis, E	1
Kochiadakis, G	1
Lekakis, J	1
Vardas, PE	1
Alexopoulos, D	1
Briguori, C	1
Quintavalle, C	1
Donahue, M	1
D'Alessio, F	1
D'Amore, C	1
Signoriello, G	1
De Caterina, R	1
Condorelli, G	1
Wang, J	1
Xu, J	1
Chen, Y	1
He, Z	1
Hultgårdh-Nilsson, A	1
Liang, C	1
Capodanno, D	5
Park, KW	2
Kang, J	1
Park, JJ	3
Yang, HM	2
Kwon, YW	1
Lee, HY	2
Kang, HJ	2
Koo, BK	2
Oh, BH	2
Park, YB	2
Kim, HS	4
Baber, U	2
Bander, J	1
Karajgikar, R	1
Yadav, K	1
Hadi, A	1
Theodoropolous, K	1
Gukathasan, N	1
Roy, S	1
Sayeneni, S	1
Scott, SA	1
Kovacic, JC	1
Yu, J	2
Sartori, S	2
Uribarri, J	1
Badimon, JJ	1
Muntner, P	1
Moreno, P	1
Kini, AS	2
Sharma, SK	1
Leoncini, M	1
Toso, A	2
Maioli, M	1
Giusti, B	1
Marcucci, R	2
Abbate, R	2
Bellandi, F	1
Tello-Montoliu, A	2
Patel, R	2
Darlington, A	3
Wilson, RE	1
Muñiz-Lozano, A	1
Desai, B	3
Bender, N	1
Sakariassen, KS	1
Mizobe, M	1
Hokimoto, S	1
Akasaka, T	1
Arima, Y	1
Kaikita, K	1
Morita, K	1
Miyazaki, H	1
Oniki, K	1
Nakagawa, K	1
Ogawa, H	1
Mohareb, MW	1
Abd Elghany, M	1
Sabry, NA	1
Farid, SF	1
Daels, FP	1
Gaizauskas, A	1
Rioja, J	1
Varshney, AK	1
Erkan, E	1
Ozgok, Y	1
Melekos, M	1
de la Rosette, JJ	1
Lee, SA	1
Suh, JW	1
Cho, YS	1
Youn, TJ	1
Kim, SH	1
Choi, DJ	1
Siasos, G	1
Oikonomou, E	1
Zaromitidou, M	1
Kioufis, S	1
Kokkou, E	1
Mourouzis, K	1
Vlasis, K	1
Vavuranakis, M	1
Stone, PH	1
Papavassiliou, AG	1
Tousoulis, D	1
Valenti, R	1
Cantini, G	1
Marrani, M	1
Migliorini, A	1
Carrabba, N	1
Comito, V	1
Vergara, R	1
Cerisano, G	1
Parodi, G	1
Gori, AM	1
Gensini, GF	1
Antoniucci, D	1
Thukkani, AK	1
Agrawal, K	1
Prince, L	1
Smoot, KJ	1
Dufour, AB	1
Cho, K	1
Gagnon, DR	1
Sokolovskaya, G	1
Ly, S	1
Temiyasathit, S	1
Faxon, DP	1
Gaziano, JM	1
Kinlay, S	1
Bittl, JA	1
Clavijo, LC	1
Maya, J	1
Carlson, G	1
Caplan, R	1
Price, MJ	1
Nakagawa, I	1
Park, HS	1
Yokoyama, S	1
Wada, T	1
Hironaka, Y	1
Motoyama, Y	1
Takayama, K	1
Kichikawa, K	1
Nakase, H	1
Schoos, MM	1
Dangas, GD	1
Kirtane, AJ	2
Litherland, C	2
Clemmensen, P	1
Stuckey, TD	1
Witzenbichler, B	2
Weisz, G	2
Rinaldi, MJ	1
Neumann, FJ	1
Metzger, DC	1
Henry, TD	2
Cox, DA	1
Duffy, PL	1
Brodie, BR	1
Mazzaferri, EL	1
Maehara, A	1
Stone, GW	2
Bell, DS	1
Barbieri, L	1
Schaffer, A	1
Marino, P	1
Bellomo, G	1
Giustino, G	1
Cohen, DJ	2
Ariti, C	1
Gibson, CM	1
Krucoff, MW	2
Moliterno, DJ	1
Colombo, A	2
Chieffo, A	1
Steg, PG	1
Pocock, S	1
Huynh, K	1
Crimi, G	1
Calabrò, P	1
Piscione, F	1
Cattaneo, M	1
Maffeo, D	1
Bartorelli, A	1
Palmieri, C	1
De Carlo, M	1
Barozzi, C	1
Tomasi, L	1
Della Riva, D	1
Palmerini, T	1
Samant, S	1
Jiang, XL	1
Peletier, LA	1
Shuldiner, AR	1
Horenstein, RB	1
Lewis, JP	1
Lesko, LJ	1
Schmidt, S	1
Buck, J	1
Kaboli, P	1
Gage, BF	1
Cram, P	1
Vaughan Sarrazin, MS	1
Storey, RF	1
Parker, WA	1
Kukula, K	1
Klopotowski, M	1
Kunicki, PK	1
Jamiolkowski, J	1
Debski, A	1
Bekta, P	1
Polanska-Skrzypczyk, M	1
Chmielak, Z	1
Witkowski, A	1
Levine, GN	1
Bakaeen, FG	1
Zuliani Mauro, MF	1
Mangione, JA	1
Costa, JR	2
Costa, R	2
Piva E Mattos, LA	1
Staico, R	2
Feres, F	2
Siqueira, D	1
Sousa, A	2
Abizaid, A	2
Brar, SS	1
Kim, J	1
Brar, SK	1
Zadegan, R	1
Ree, M	1
Liu, IL	1
Mansukhani, P	1
Aharonian, V	1
Hyett, R	1
Shen, AY	1
Prasad, A	1
Tsimikas, S	1
Serebruany, V	1
Pokov, I	1
Kuliczkowski, W	1
Chesebro, J	1
Badimon, J	1
Cerbone, AM	1
Macarone-Palmieri, N	1
Saldalamacchia, G	1
Coppola, A	1
Di Minno, G	1
Rivellese, AA	1
Wilhelmsen, L	1
Welin, L	1
Odén, A	1
Björnberg, A	1
Roffi, M	2
Eberli, FR	1
Suryadevara, S	1
Depta, JP	1
Cannon, CP	2
Fonarow, GC	1
Zhao, X	1
Peacock, WF	1
Stellos, K	1
Bigalke, B	1
Stakos, D	1
Henkelmann, N	1
Gawaz, M	1
Gaborit, B	3
Frère, C	2
Cuisset, T	3
Alessi, MC	3
Dutour, A	3
Liistro, F	1
Fineschi, M	1
Grotti, S	1
Angioli, P	1
Carrera, A	1
Ducci, K	1
Gori, T	1
Falsini, G	1
Pierli, C	1
Bolognese, L	1
Bernardo, E	3
Vivas, D	1
Sabaté, M	3
Ferreiro, JL	3
Ueno, M	3
Jimenez-Quevedo, P	3
Alfonso, F	3
Bass, TA	5
Macaya, C	3
Fernandez-Ortiz, A	3
Morel, O	2
Kessler, L	1
Ohlmann, P	2
Bareiss, P	1
Amin, AP	1
Marso, SP	2
Jeon, KH	1
Kang, SH	1
Oh, IY	1
Cho, HJ	1
Tentzeris, I	1
Siller-Matula, J	1
Farhan, S	1
Jarai, R	1
Wojta, J	1
Huber, K	1
Dharmashankar, K	1
Sumner, S	1
Charlton, RK	1
Box, LC	1
Zenni, M	1
Guzman, LA	2
Carballo, S	1
Carballo, D	1
Keller, PF	1
Yan, BP	1
Ajani, AE	1
Clark, DJ	1
Duffy, SJ	1
Andrianopoulos, N	1
Brennan, AL	1
Loane, P	1
Reid, CM	1
Barone-Rochette, G	1
Foote, A	1
Motreff, P	1
Vanzetto, G	1
Quesada, JL	1
Danchin, N	1
Machecourt, J	1
Awad, HH	1
Zubaid, M	1
Alsheikh-Ali, AA	1
Al Suwaidi, J	1
Anderson, FA	1
Gore, JM	1
Goldberg, RJ	1
Navarese, EP	1
D'Urbano, M	1
Savonitto, S	1
Collet, CA	1
Chamié, D	1
Siquera, D	1
Obregon, J	1
Sousa, JE	1
Osmancik, P	1
Paulu, P	1
Tousek, P	1
Kocka, V	1
Widimsky, P	1
Kreutz, RP	1
Nystrom, P	1
Kreutz, Y	1
Miao, J	1
Kovacs, R	1
Desta, Z	1
Flockhart, DA	1
Jin, Y	1
White, CL	1
Szychowski, JM	1
Roldan, A	1
Benavente, MF	1
Pretell, EJ	1
Del Brutto, OH	1
Kase, CS	1
Arauz, A	1
Meyer, BC	1
Meissner, I	1
Demaerschalk, BM	1
McClure, LA	1
Coffey, CS	1
Pearce, LA	1
Conwit, R	1
Irby, LH	1
Peri, K	1
Pergola, PE	1
Hart, RG	1
Benavente, OR	1
El Ghannudi, S	1
Hess, S	1
Reydel, A	1
Crimizade, U	1
Jesel, L	1
Radulescu, B	1
Wiesel, ML	1
Gachet, C	1
Li, Y	2
Han, Y	1
Zhang, L	1
Jing, Q	1
Wang, X	1
Yan, G	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention[NCT01603082]	Phase 4	343 participants (Actual)	Interventional	2012-07-31	Completed
Impact of LDL-cholesterol Lowering on Platelet Activation[NCT03331666]	Phase 4	4 participants (Actual)	Interventional	2018-11-16	Terminated (stopped due to Terminated Prematurely due to COVID-19)
A Multicenter Randomized Trial Evaluating the Efficacy of Sarpogrelate on Ischemic Heart Disease After Drug-eluting Stent Implantation in Patients With Diabetes Mellitus or Renal Impairment[NCT02294643]	Phase 3	220 participants (Actual)	Interventional	2009-04-30	Completed
Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients: An Observational Single-Arm Study (The PARIS Registry)[NCT00998127]		5,031 participants (Actual)	Observational	2009-06-30	Completed
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242]	Phase 4	9,006 participants (Actual)	Interventional	2015-07-31	Completed
The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093]		280 participants (Actual)	Observational	2014-06-30	Completed
Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel[NCT01328470]	Phase 4	85 participants (Actual)	Interventional	2009-09-30	Completed
DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function[NCT02377388]	Phase 3	74 participants (Actual)	Interventional	2017-02-07	Completed
Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent[NCT00331578]	Phase 4	2,077 participants (Actual)	Interventional	2006-06-30	Completed
SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT00697372]	Phase 4	150 participants (Actual)	Interventional	2007-09-30	Completed
Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions)[NCT01278186]	Phase 4	190 participants (Anticipated)	Interventional	2010-06-30	Active, not recruiting
Prospective, Randomized, Single-Center Evaluation of the Cypher™ Sirolimus Eluting Coronary Stent System in the Treatment of Bifurcated Coronary Lesions[NCT00288535]	Phase 4	200 participants (Anticipated)	Interventional	2005-03-31	Recruiting
Study of Lipid Core Plaque Shift at Sites of Native Coronary Artery Bifurcation[NCT00905671]	Phase 4	20 participants (Actual)	Interventional	2009-06-30	Completed
Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT01200693]	Phase 4	80 participants (Actual)	Interventional	2008-11-30	Completed
Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612]	Phase 3	200 participants (Actual)	Interventional	2005-06-30	Completed
Phase 4 Study of Randomized Comparison Among Oral Rapamycin Plus Bare Metal Stents Versus Drug Eluting Stents in de Novo Coronary Lesions.[NCT00552669]	Phase 4	200 participants (Actual)	Interventional	2006-01-31	Completed
Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733]	Phase 4	80 participants (Actual)	Interventional	2009-05-31	Completed
Multi-Center, Single-Blind, Two-Arm, Randomized, Controlled, Non Inferiority Trial of the Conor CoStar Paclitaxel-Eluting Coronary Stent System vs the TAXUS DES in Patients With De Novo Lesions of the Native Coronary Arteries[NCT00165035]	Phase 3	1,701 participants (Actual)	Interventional	2005-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Participants with low (<150) baseline PRU values were excluded. (NCT01603082)
Timeframe: 2 hours after the loading dose

Inhibition of the P2Y12 Receptor at 0.5 Hours, End of PCI, and 8 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by PRU From VerifyNow™

Intervention	PRU (Mean)
Ticagrelor	98.4
Clopidogrel	257.5

Participants with low (<150) baseline PRU values were excluded. (NCT01603082)
Timeframe: 0.5 hours, end of PCI, and 8 hours after the loading dose

Adenosine Di-phosphate (ADP) Induced, P2Y12 Dependent and Arachidonic Acid Induced Platelet Activation (Aspirin Reaction Unit (ARU))

Intervention	PRU (Mean)
	0.5 hours	8 hours	End of PCI (n=41 for ticagrelor)
Clopidogrel	297.7	202.3	307.8
Ticagrelor	277.3	43.8	264.2

ADP- or arachidonic acid-stimulated platelet aggregation as assessed by the commercially-available VerifyNow Aspirin assay (Accriva Diagnostics) will be performed. Unit: Aspirin Reaction Unit (ARU) (NCT03331666)
Timeframe: Day 7, Day 14, Day 21, Day 28, Day 84

Adenosine Di-phosphate (ADP) Induced, P2Y12 Dependent and Arachidonic Acid Induced Platelet Activation (P2Y12 Reaction Units (PRU))

Intervention	ARU (Number)
	Aspirin Test, Day 7	Aspirin Test Day 14	Aspirin Test, Day 21	Aspirin Test, Day 28	Aspirin Test, Day 84
Evolocumab	521	608	533	530	406
Placebo	432	401	490	512	386

ADP- or arachidonic acid-stimulated platelet aggregation as assessed by the commercially-available VerifyNow P2Y12 (VerifyNow PRUTest) will be performed. Unit: PRU (NCT03331666)
Timeframe: Day 7, Day 14, Day 21, Day 28, Day 84

Number of Participants With BARC Type 2, 3, or 5

Intervention	PRU (Number)
	P2Y12 Test, Day 7	P2Y12 Test, Day 14	P2Y12 test, Day 21	P2Y12 Test, Day 28	P2Y12 Test, Day 84
Evolocumab	266	268	268	276	256
Placebo	216	226	233	225	267

Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization

Number of Participants With Ischemic Episode

Intervention	Participants (Count of Participants)
Placebo + Ticagrelor	141
Aspirin + Ticagrelor	250

Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization

Differences in Costs Between Two Revascularization Strategies for de Novo Coronary Lesions.

Intervention	Participants (Count of Participants)
Placebo + Ticagrelor	135
Aspirin + Ticagrelor	137

Overall costs expressed in US dollars at 18 months of follow up between Oral Sirolimus Plus BMS vs DES implantation in denovo coronary lesions. (NCT00552669)
Timeframe: Follow up will be conducted by the coordinating Center at 18 months of follow up

Target Vessel Revascularization (TVR)

Intervention	US dollars (Mean)
Oral Sirolimus + Bare Metal Stent	5483
Drug Eluting Stents	7658.2

Efficacy end point was TVR as revasacularization of the treated vessel. (NCT00552669)
Timeframe: 18 months

Major Adverse Cardiovascular Events (MACCE)

Intervention	vessels (Number)
Oral Sirolimus + Bare Metal Stent	14
Drug Eluting Stents	15

Death from any cause, myocardial infarction and stroke. Safety was analyzed as MACCE (major adverse cardiovascular events) including death, MI and stroke. (NCT00552669)
Timeframe: 18 Months

Article	Year
Dual antiplatelet therapy in patients with diabetes mellitus: special considerations. Expert review of cardiovascular therapy, 2013, Volume: 11, Issue:3 Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus; Diabetic Angiopat	2013
Diabetes, vascular complications and antiplatelet therapy: open problems. Acta diabetologica, 2009, Volume: 46, Issue:4 Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Diabetic Angiopathies; Drug Interactions; Drug Resistance;	2009
Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Diabetic Angiopathies; Drug Resistance; Humans; Platelet Ac	2009
Diabetes and acute coronary syndromes. Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:3 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Dia	2009
Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:3 Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Drug Resistance; Endothelium, Vascular; Humans; Ischemia; O	2009
Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis. Atherosclerosis, 2010, Volume: 212, Issue:2 Topics: Acute Coronary Syndrome; Apoptosis; Aspirin; Blood Platelets; Clopidogrel; Diabetes Complications; D	2010
Acute coronary syndrome in the patient with diabetes: is the management different? Current cardiology reports, 2010, Volume: 12, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Diabetes Melli	2010
Platelet function variability and non-genetic causes. Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1 Topics: Blood Platelets; Clinical Trials as Topic; Clopidogrel; Comorbidity; Coronary Artery Disease; Diabet	2011
Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor. Current medical research and opinion, 2011, Volume: 27, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Diabetes Mellitus; Fema	2011
Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Archives of internal medicine, 2004, Oct-25, Volume: 164, Issue:19 Topics: Angina, Unstable; Aspirin; Clopidogrel; Comorbidity; Diabetes Mellitus; Humans; Hypercholesterolemia	2004
[Cardiovascular risk in diabetes--diagnostic and therapeutic aspects]. MMW Fortschritte der Medizin, 2004, Sep-02, Volume: 146, Issue:35-36 Topics: Abciximab; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Mon	2004

Article	Year
Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization. American heart journal, 2017, Volume: 188 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Diabetes Mellitus; Dose-Response Relationship,	2017
Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status. Journal of thrombosis and thrombolysis, 2014, Volume: 37, Issue:4 Topics: Aged; Atorvastatin; Clopidogrel; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylgl	2014
Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. Journal of thrombosis and thrombolysis, 2014, Volume: 37, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery D	2014
The impact of a 600-mg loading dose of clopidogrel in diabetic and non-diabetic patients undergoing elective PCI. Minerva cardioangiologica, 2016, Volume: 64, Issue:4 Topics: Aged; Clopidogrel; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Percutaneous Coronary Inter	2016
Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study. Contemporary clinical trials, 2015, Volume: 43 Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus; Drug Therapy, Co	2015
Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus. Cardiovascular revascularization medicine : including molecular interventions, 2015, Volume: 16, Issue:8 Topics: Adenosine; Administration, Oral; Aged; Chi-Square Distribution; Clopidogrel; Coronary Angiography; C	2015
Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study). The American journal of cardiology, 2016, Jan-15, Volume: 117, Issue:2 Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Diabetes Mellitus; Drug-Eluting Stents; Femal	2016
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients. The Journal of invasive cardiology, 2017, Volume: 29, Issue:3 Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Corona	2017
Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thrombosis and haemostasis, 2011, Volume: 106, Issue:2 Topics: Aged; Aspirin; Blood Platelets; Chemotherapy, Adjuvant; Cilostazol; Clopidogrel; Cross-Over Studies;	2011
Assessing the temporal course of neointimal hyperplasia formation after different generations of drug-eluting stents. JACC. Cardiovascular interventions, 2011, Volume: 4, Issue:10 Topics: Clopidogrel; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus; Drug-Eluting Stents; Fema	2011
High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel. Journal of thrombosis and thrombolysis, 2012, Volume: 33, Issue:4 Topics: Age Factors; Aged; Biomarkers; CD40 Ligand; Clopidogrel; Diabetes Mellitus; Drug Resistance; Female;	2012
Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:6 Topics: Aged; Antihypertensive Agents; Aspirin; Black or African American; Blood Pressure; Chi-Square Distri	2013
Randomized controlled trial of symptomatic middle cerebral artery stenosis: endovascular versus medical therapy in a Chinese population. Stroke, 2012, Volume: 43, Issue:12 Topics: Adult; Aged; Angioplasty; Asian People; Aspirin; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combi	2012
Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus. Journal of thrombosis and thrombolysis, 2013, Volume: 36, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus;	2013
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. The American journal of cardiology, 2002, Sep-15, Volume: 90, Issue:6 Topics: Aged; Aspirin; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endpoi	2002
Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). The American journal of cardiology, 2002, Oct-01, Volume: 90, Issue:7 Topics: Age Factors; Aged; Aspirin; Clopidogrel; Creatinine; Diabetes Mellitus; Female; Humans; Male; Massac	2002
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, Mar-16, Volume: 109, Issue:10 Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;	2004
Effect of ticlopidine on monocyte-derived microparticles and activated platelet markers in diabetes mellitus. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2004, Volume: 10, Issue:2 Topics: Antigens, CD; Biomarkers; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Monocytes; P-Selecti	2004
Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation, 2004, Aug-03, Volume: 110, Issue:5 Topics: Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clopidogrel; Coronary Restenosis; Cost-Bene	2004
The effect of tirofiban and clopidogrel pretreatment on outcome of old saphenous vein graft stenting in patients with acute coronary syndromes. The Tohoku journal of experimental medicine, 2005, Volume: 206, Issue:1 Topics: Acute Disease; Clopidogrel; Coronary Disease; Diabetes Mellitus; Female; Humans; Male; Middle Aged;	2005
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im Journal of the American College of Cardiology, 2008, Mar-25, Volume: 51, Issue:12 Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest	2008
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. Journal of the American College of Cardiology, 2008, Apr-22, Volume: 51, Issue:16 Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Chromium All	2008
The influence of ticlopidine on the natural course of retinal vein occlusion. Agents and actions. Supplements, 1984, Volume: 15 Topics: Adenosine Diphosphate; Adult; Aged; Anticoagulants; Clinical Trials as Topic; Diabetes Mellitus; Fem	1984

Article	Year
The comparison between the effects of aspirin and clopidogrel monotherapy on postoperative bleeding in diabetic patients after off-pump coronary artery bypass surgery. Reviews in cardiovascular medicine, 2021, Sep-24, Volume: 22, Issue:3 Topics: Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Diabetes Mellitus; Humans; Platelet Aggregat	2021
Cost Utility of Prasugrel in Postangioplasty Diabetic Patients. Value in health regional issues, 2022, Volume: 30 Topics: Clopidogrel; Diabetes Mellitus; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhi	2022
Effect of Cilostazol on Patients With Diabetes Who Underwent Endovascular Treatment for Peripheral Artery Disease. Journal of the American Heart Association, 2023, 06-20, Volume: 12, Issue:12 Topics: Cilostazol; Diabetes Mellitus; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors;	2023
De-escalation of oral P2Y EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2019, Aug-09, Volume: 15, Issue:6 Topics: Acute Coronary Syndrome; Blood Platelets; Diabetes Mellitus; Drug Monitoring; Humans; Percutaneous C	2019
Gender Differences in Platelet Reactivity in Diabetic Patients Receiving Dual Antiplatelet Therapy. Cardiovascular revascularization medicine : including molecular interventions, 2020, Volume: 21, Issue:9 Topics: Adenosine; Aftercare; Aspirin; Blood Platelets; Diabetes Mellitus; Drug Therapy, Combination; Female	2020
Differential Impact of Clinical and Genetic Factors on High Platelet Reactivity in Patients with Coronary Artery Disease Treated with Clopidogrel and Prasugrel. Journal of atherosclerosis and thrombosis, 2022, Jul-01, Volume: 29, Issue:7 Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus;	2022
Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. Journal of the American Heart Association, 2017, Mar-29, Volume: 6, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Comorbidity; Diabetes Mellit	2017
Recommendations on the Clinical Use of Compound Danshen Dripping Pills. Chinese medical journal, 2017, Apr-20, Volume: 130, Issue:8 Topics: Angina Pectoris; Aspirin; Camphanes; Clopidogrel; Coronary Disease; Diabetes Mellitus; Diabetic Neph	2017
Management of diabetic patients hospitalized for acute coronary syndromes: a prospective multicenter registry. Journal of cardiovascular medicine (Hagerstown, Md.), 2017, Volume: 18, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Diab	2017
Evaluation of On-Clopidogrel platelet reactivity overtime, SYNTAX SCORE, genetic polymorphisms and their relationship to one year clinical outcomes in STEMI patients undergoing PCI. Minerva cardioangiologica, 2018, Volume: 66, Issue:1 Topics: Adult; Aged; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Diabetes Mellitus; Female; Foll	2018
Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease. Pharmacotherapy, 2017, Volume: 37, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cohort Studies; Diabetes Mellitus; Drug Utilization	2017
Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy. Coronary artery disease, 2018, Volume: 29, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; Case-Control Studies; Clopidogrel; Cohort Studies; Comorbi	2018
Predictors of strut coverage of drug eluting stent implantation in diabetic patients- Is only on-clopidogrel platelet reactivity enough? Reply. International journal of cardiology, 2019, 05-15, Volume: 283 Topics: Blood Platelets; Clopidogrel; Diabetes Mellitus; Drug-Eluting Stents; Humans; Ticlopidine	2019
Predictors of strut coverage of drug eluting stent in diabetic patients - Is only on-clopidogrel platelet reactivity enough? International journal of cardiology, 2019, 08-01, Volume: 288 Topics: Blood Platelets; Clopidogrel; Diabetes Mellitus; Drug-Eluting Stents; Humans; Ticlopidine	2019
Thiazolidinedione usage is associated with decreased response to clopidogrel in DM patients. International journal of cardiology, 2013, Sep-20, Volume: 168, Issue:1 Topics: Aged; Clopidogrel; Cohort Studies; Diabetes Mellitus; Drug Interactions; Female; Humans; Male; Middl	2013
Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. Thrombosis and haemostasis, 2013, Volume: 110, Issue:1 Topics: Aged; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Female; Humans; Kidney Diseases; Male;	2013
Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients. Thrombosis research, 2014, Volume: 134, Issue:1 Topics: Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus; Female; Gen	2014
Age-related prevalence of diabetes mellitus, cardiovascular disease and anticoagulation therapy use in a urolithiasis population and their effect on outcomes: the Clinical Research Office of the Endourological Society Ureteroscopy Global Study. World journal of urology, 2015, Volume: 33, Issue:6 Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cardiovascula	2015
Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy. Atherosclerosis, 2015, Volume: 242, Issue:1 Topics: Activation, Metabolic; Aged; Aspirin; Brachial Artery; Clopidogrel; Coronary Disease; Cytochrome P-4	2015
Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus. International journal of cardiology, 2015, Dec-15, Volume: 201 Topics: Aged; Blood Platelets; Chronic Disease; Clopidogrel; Coronary Occlusion; Diabetes Mellitus; Dose-Res	2015
Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting. Journal of the American College of Cardiology, 2015, Sep-08, Volume: 66, Issue:10 Topics: Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cohort Stud	2015
Dual-Antiplatelet Therapy for Diabetic Patients After Stent Implantation: Lessons From an Observational Study. Journal of the American College of Cardiology, 2015, Sep-08, Volume: 66, Issue:10 Topics: Angioplasty, Balloon, Coronary; Cause of Death; Coronary Artery Disease; Diabetes Mellitus; Female;	2015
Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2016, Volume: 25, Issue:1 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Cilostazol; Clopidogrel; Dia	2016
Aspirin in the prevention of cardiovascular events in patients with diabetes. Postgraduate medicine, 2016, Volume: 128, Issue:2 Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Drug Admin	2016
Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy. Journal of thrombosis and thrombolysis, 2016, Volume: 42, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combinati	2016
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. Journal of the American College of Cardiology, 2016, May-17, Volume: 67, Issue:19 Topics: Acute Coronary Syndrome; Age Factors; Aged; Anemia; Aspirin; Body Mass Index; Clopidogrel; Cohort St	2016
Antiplatelet therapy: Ticagrelor reduces cardiac events in patients with PAD or diabetes. Nature reviews. Cardiology, 2016, Volume: 13, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Tica	2016
Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2016, Jun-20, Volume: 12, Issue:3 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Blood Platelets; C	2016
Identifying clinically relevant sources of variability: The clopidogrel challenge. Clinical pharmacology and therapeutics, 2017, Volume: 101, Issue:2 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Body Mass Index; Clopidogrel; Computer Simulatio	2017
Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System. American heart journal, 2016, Volume: 179 Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Clopidogrel; Dabigatran	2016
Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus. Circulation, 2016, Sep-13, Volume: 134, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Diabetes Mellitus; Humans; Percutaneous Coronar	2016
Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome. BMC cardiovascular disorders, 2016, 12-08, Volume: 16, Issue:1 Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Diabetes Mellitus; Female; Follow-Up Studies; Graft Occl	2016
Adding CABG to the Dual Antiplatelet Salad. Journal of the American College of Cardiology, 2017, 01-17, Volume: 69, Issue:2 Topics: Aspirin; Coronary Artery Bypass; Diabetes Mellitus; Freedom; Humans; Platelet Aggregation Inhibitors	2017
Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. Journal of the American College of Cardiology, 2008, Jun-10, Volume: 51, Issue:23 Topics: Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Drug-Eluting Stents; F	2008
The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents. Journal of the American College of Cardiology, 2008, Jun-10, Volume: 51, Issue:23 Topics: Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Drug-Eluting Stents; H	2008
Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thrombosis and haemostasis, 2008, Volume: 100, Issue:1 Topics: Aged; Aspirin; Baltimore; Biomarkers; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Femal	2008
Saving lives, money and resources: drug and CABG/PCI use after myocardial infarction in a Swedish record-linkage study. The European journal of health economics : HEPAC : health economics in prevention and care, 2010, Volume: 11, Issue:2 Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Ant	2010
Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. The American journal of cardiology, 2009, Nov-01, Volume: 104, Issue:9 Topics: Acute Coronary Syndrome; Aged; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atri	2009
Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication. Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:1 Topics: Acute Coronary Syndrome; Angina Pectoris; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronar	2010
Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control. Journal of thrombosis and haemostasis : JTH, 2009, Volume: 7, Issue:11 Topics: Blood Glucose; Clopidogrel; Diabetes Mellitus; Fibrinogen; Humans; Platelet Activation; Platelet Agg	2009
Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. Journal of the American College of Cardiology, 2010, Feb-16, Volume: 55, Issue:7 Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Restenosis; Coronary	2010
Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. Journal of the American College of Cardiology, 2010, Mar-16, Volume: 55, Issue:11 Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Diabe	2010
Glycemic control and clopidogrel response. American heart journal, 2010, Volume: 159, Issue:6 Topics: Blood Glucose; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus; Glycated Hemoglobin; Glycemi	2010
Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans. Cardiovascular therapeutics, 2012, Volume: 30, Issue:1 Topics: Age Factors; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Asian People; Biomarkers; B	2012
[Specificities of diabetes in acute coronary syndromes]. Revue medicale suisse, 2011, Jun-01, Volume: 7, Issue:297 Topics: Acute Coronary Syndrome; Algorithms; Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Clopidogr	2011
Recent trends in Australian percutaneous coronary intervention practice: insights from the Melbourne Interventional Group registry. The Medical journal of Australia, 2011, Aug-01, Volume: 195, Issue:3 Topics: Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Australia; Clopidogrel; Comorb	2011
Stent-related cardiac events beyond three years after implantation of the sirolimus-eluting stent (from the EVASTENT Patients). The American journal of cardiology, 2011, Nov-15, Volume: 108, Issue:10 Topics: Clopidogrel; Cohort Studies; Coronary Artery Disease; Coronary Thrombosis; Diabetes Mellitus; Drug-E	2011
Comparison of characteristics, management practices, and outcomes of patients between the global registry and the gulf registry of acute coronary events. The American journal of cardiology, 2011, Nov-01, Volume: 108, Issue:9 Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Aspiri	2011
Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin. Platelets, 2013, Volume: 24, Issue:2 Topics: Adenosine Diphosphate; Aged; Alprostadil; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytoc	2013
The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight. Thrombosis and haemostasis, 2012, Volume: 108, Issue:2 Topics: Acute Coronary Syndrome; Aged; Body Weight; Clopidogrel; Diabetes Complications; Diabetes Mellitus;	2012
Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Jun-01, Volume: 81, Issue:7 Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Cor	2013
Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes. JAMA, 2012, Sep-05, Volume: 308, Issue:9 Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Data Collection	2012
Antiplatelet therapy following myocardial infarction in patients with diabetes. JAMA, 2012, Sep-05, Volume: 308, Issue:9 Topics: Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus; Female; Humans; Male; Myocardial Infarction	2012
Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. International journal of cardiology, 2013, Sep-20, Volume: 168, Issue:1 Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Diabetes Mellitus; Female; Follow-Up St	2013
Pharmaceutical care for patients with acute myocardial infarction in Hungary. International journal of clinical pharmacology and therapeutics, 2013, Volume: 51, Issue:2 Topics: Acute Disease; Adult; Aged; Aspirin; Clopidogrel; Comorbidity; Diabetes Mellitus; Drug Therapy, Comb	2013
Treatment with clopidogrel after myocardial infarction. JAMA, 2012, Dec-19, Volume: 308, Issue:23 Topics: Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Male; Myocardial Infarction; Platelet Ag	2012
Treatment with clopidogrel after myocardial infarction. JAMA, 2012, Dec-19, Volume: 308, Issue:23 Topics: Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Male; Myocardial Infarction; Platelet Ag	2012
Ticlopidine-induced marrow aplasia treated with cyclosporine. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2002, Volume: 8, Issue:2 Topics: Bone Marrow Diseases; Cyclosporine; Diabetes Complications; Diabetes Mellitus; Humans; Male; Middle	2002
Clopidogrel and percutaneous coronary interventions. JAMA, 2003, Apr-16, Volume: 289, Issue:15 Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Diabetes Mellitus; Drug Administration Schedul	2003
[Prophylaxis of stroke]. Praxis, 2005, Jul-27, Volume: 94, Issue:30-31 Topics: Age Factors; Aged; Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fi	2005
Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. The American journal of cardiology, 2006, Jan-01, Volume: 97, Issue:1 Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Collagen Type I;	2006
Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes, 2006, Volume: 55, Issue:3 Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Fema	2006
[Postoperative antithrombotic treatment in diabetic patients]. Clinical research in cardiology : official journal of the German Cardiac Society, 2006, Volume: 95 Suppl 1 Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mell	2006
Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Circulation, 2007, Jun-26, Volume: 115, Issue:25 Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Angi	2007
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations]. Ugeskrift for laeger, 2008, Mar-31, Volume: 170, Issue:14 Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin;	2008
Ticlopidine may reduce functional fibrinogen levels by inhibition of MPC incorporation into fibrin. Thrombosis and haemostasis, 1997, Volume: 77, Issue:3 Topics: Diabetes Mellitus; Fibrin; Fibrinogen; Fibrinolytic Agents; Humans; Macromolecular Substances; Ticlo	1997
[Ticlopidine, diarrhea and lymphocytic colitis]. Gastroenterologie clinique et biologique, 1998, Volume: 22, Issue:4 Topics: Aged; Aged, 80 and over; Colitis; Diabetes Complications; Diabetes Mellitus; Diarrhea; Female; Human	1998
Sex differences and similarities in the management and outcome of stroke patients. Stroke, 2000, Volume: 31, Issue:8 Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Comorbidity;	2000
Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention. Prescrire international, 2000, Volume: 9, Issue:47 Topics: Aspirin; Carotid Stenosis; Cost-Benefit Analysis; Diabetes Mellitus; Digestive System; Female; Human	2000
Close relationship between the platelet activation marker CD62 and the granular release of platelet-derived growth factor. The Journal of pharmacology and experimental therapeutics, 2002, Volume: 300, Issue:3 Topics: Abciximab; Adult; Antibodies, Monoclonal; Blood Platelets; Clopidogrel; Cytoplasmic Granules; Diabet	2002
Inhibition of ticlopidine of platelet adhesion to human venous subendothelium in patients with diabetes. The Journal of laboratory and clinical medicine, 1988, Volume: 112, Issue:5 Topics: Adult; Bleeding Time; Diabetes Mellitus; Diabetes Mellitus, Type 1; Endothelium, Vascular; Female; F	1988

Intervention	participants (Number)
	MACCE	Death	Acute Myocardial Infarction	Stroke
Drug Eluting Stents	15	7	9	1
Oral Sirolimus + Bare Metal Stent	9	3	6	0

ticlopidine and Diabetes Mellitus